Trial Profile
Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms MADONNA
- 31 Aug 2019 Status changed from suspended to completed.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 23 Mar 2013 Status changed from recruiting to suspended as reported by European Clinical Trials Database.